Home Newsfeeds Oppenheimer Assumes Victory Capital Holdings at Perform

Oppenheimer Assumes Victory Capital Holdings at Perform

Oppenheimer analyst Chris Kotowski assumes Victory Capital Holdings (NASDAQ:VCTR) with a Perform rating.

byBenzinga Newsdesk

August 9, 2022

1 minute read

Oppenheimer analyst Chris Kotowski assumes Victory Capital Holdings (NASDAQ:VCTR) with a Perform rating.

NANOBIOTIX Announces Presentation Of First Data From Phase 1 Study Evaluating NBTXR3 For Patients With Locally Advanced Pancreatic Cancer

By Benzinga Newsdesk

September 28, 4:17 PM

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer ResearchPreliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy activation remains

NBTX

Analyst Ratings

Where ChemoCentryx Stands With Analysts

By Benzinga Insights

August 5, 12:02 PM

Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

CCXI

Analyst Ratings

Where Parker Hannifin Stands With Analysts

By Benzinga Insights

July 12, 10:00 AM

Within the last quarter, Parker Hannifin (NYSE:PH) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

Guggenheim Creates Bullish Pitch For ANI Pharma On Progress With Cortrophin Launch

By Vandana Singh

March 1, 3:16 PM

Guggenheim launched its coverage on ANI Pharmaceuticals Inc (NASDAQ:ANIP) with a price target of $55 and a Buy recommendation citing a “bullish view”…

ANIP

Oppenheimer Assumes Victory Capital Holdings at Perform

Related Posts

NANOBIOTIX Announces Presentation Of First Data From Phase 1 Study Evaluating NBTXR3 For Patients With Locally Advanced Pancreatic Cancer

Where ChemoCentryx Stands With Analysts

Where Parker Hannifin Stands With Analysts

Guggenheim Creates Bullish Pitch For ANI Pharma On Progress With Cortrophin Launch